Egetis’ Nomination Committee for the 2027 Annual General Meeting
21 oktober, 18:00
Stockholm, Sweden, October 21, 2026. Egetis Therapeutics AB (publ) (NASDAQ Stockholm: EGTX) today announced the composition of the Nomination Committee for the 2027 Annual General Meeting (AGM) to be held on May 12, 2027.
The Nomination Committee, which has been appointed in accordance with the principles adopted by the Annual General Meeting held on April 14, 2026, comprises the following members:
James Brush, appointed by Frazier Life Sciences
Peter Lindell, appointed by Cidro Förvaltning AB
Peder Walberg, appointed by Cetoros AB
Mats Blom, Chairman of the Board of Directors, will co-opt to the Nomination Committee.
The Committee's assignment is to present proposals regarding Chairman and other members of the Board, as well as remuneration to the Board´s members, to the AGM. The Nomination Committee shall also submit proposals for appointment and remuneration of auditors. Further, the Committee shall submit proposals regarding the process to appoint the Nomination Committee to the AGM in 2028.
Shareholders who wish to submit proposals to the Nomination Committee can do so by email to info@egetis.com (please label emails ‘Nomination Committee’). Proposals should be submitted no later than January 22, 2027.
For further information, please contact
Karl Hård, Head of Investor Relations, Communications & Business Development
Lena Wange, Investor Relations Director
ir@egetis.com
About Egetis Therapeutics
Egetis Therapeutics is a commercial-stage pharmaceutical company focused on developing and delivering innovative therapies for patients with rare diseases with significant unmet medical need. Combining scientific and clinical expertise with integrated late-stage development, regulatory and commercial capabilities and manufacturing expertise, Egetis is committed to delivering treatments and dedicated support to underserved patient communities.
The Company's lead product, EMCITATE® (tiratricol), is the first and only approved treatment for MCT8 deficiency, a rare and life-shortening genetic disorder, with marketing authorizations in the European Union and in the United States.
Headquartered in Stockholm, Sweden, with operations in the U.S. and Europe, Egetis is building a sustainable global rare disease company.
For more information, visit egetis.com and follow the Company on LinkedIn.
Ämnen i artikeln
Egetis’ Nomination Committee for the 2027 Annual General Meeting
21 oktober, 18:00
Stockholm, Sweden, October 21, 2026. Egetis Therapeutics AB (publ) (NASDAQ Stockholm: EGTX) today announced the composition of the Nomination Committee for the 2027 Annual General Meeting (AGM) to be held on May 12, 2027.
The Nomination Committee, which has been appointed in accordance with the principles adopted by the Annual General Meeting held on April 14, 2026, comprises the following members:
James Brush, appointed by Frazier Life Sciences
Peter Lindell, appointed by Cidro Förvaltning AB
Peder Walberg, appointed by Cetoros AB
Mats Blom, Chairman of the Board of Directors, will co-opt to the Nomination Committee.
The Committee's assignment is to present proposals regarding Chairman and other members of the Board, as well as remuneration to the Board´s members, to the AGM. The Nomination Committee shall also submit proposals for appointment and remuneration of auditors. Further, the Committee shall submit proposals regarding the process to appoint the Nomination Committee to the AGM in 2028.
Shareholders who wish to submit proposals to the Nomination Committee can do so by email to info@egetis.com (please label emails ‘Nomination Committee’). Proposals should be submitted no later than January 22, 2027.
For further information, please contact
Karl Hård, Head of Investor Relations, Communications & Business Development
Lena Wange, Investor Relations Director
ir@egetis.com
About Egetis Therapeutics
Egetis Therapeutics is a commercial-stage pharmaceutical company focused on developing and delivering innovative therapies for patients with rare diseases with significant unmet medical need. Combining scientific and clinical expertise with integrated late-stage development, regulatory and commercial capabilities and manufacturing expertise, Egetis is committed to delivering treatments and dedicated support to underserved patient communities.
The Company's lead product, EMCITATE® (tiratricol), is the first and only approved treatment for MCT8 deficiency, a rare and life-shortening genetic disorder, with marketing authorizations in the European Union and in the United States.
Headquartered in Stockholm, Sweden, with operations in the U.S. and Europe, Egetis is building a sustainable global rare disease company.
For more information, visit egetis.com and follow the Company on LinkedIn.
Ämnen i artikeln
Aktier
Aktieanalyser
Aktier
Aktieanalyser
Marknadsöversikt
1 DAG %
Senast
1 mån
